Skip to main content

Clinical Radiation Oncology

Section edited by Stephanie Combs, Pirus Ghadjar, Matthias Guckenberger, Daniel Habermehl, Silke Nachbichler, Maximilian Niyazi, and Falk Roeder

The Clinical Radiation Oncology section aims to provide a platform for clinical research in radiation oncology. Research includes innovative early phase and later stage clinical trials, technical approaches, review articles on “burning” clinical questions, invited key reviews, RT planning studies, multimodal therapy, data mining from retrospective cohorts in a hypothesis-generating manner, interconnection between imaging and improved target delineation, and intensity modulation/high precision techniques. The section addresses current, timely and cutting- edge research and reviews about clinically relevant issues in radiation oncology, while offering a fast review process.

Page 2 of 27

  1. Ultrahypofractionation can shorten the irradiation period. This study is the first dosimetric investigation comparing ultrahypofractionation using volumetric arc radiation therapy (VMAT) and intensity-modulate...

    Authors: Puntiwa Oonsiri, Chonnipa Nantavithya, Chawalit Lertbutsayanukul, Thanaporn Sarsitthithum, Mananchaya Vimolnoch, Tanawat Tawonwong and Kitwadee Saksornchai
    Citation: Radiation Oncology 2022 17:20
  2. Prostate cancer is the most common cancer among men, and its diagnosis and treatment are improving. Our study evaluated how PSMA-PET/CT prior to treatment planning might improve the optimal management of prost...

    Authors: Vasileios Karagiannis, Viktor Wichmann, Juha Saarinen, Natalja Eigeliene, Heidi Andersen and Antti Jekunen
    Citation: Radiation Oncology 2022 17:19
  3. Pain symptoms in the upper abdomen and back are prevalent in 80% of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC), where the current standard treatment is a systemic therapy consisting of a...

    Authors: M. Pavic, M. Niyazi, L. Wilke, S. Corradini, M. Vornhülz, U. Mansmann, A. Al Tawil, R. Fritsch, J. Hörner-Rieber, J. Debus, M. Guckenberger, C. Belka, J. Mayerle and G. Beyer
    Citation: Radiation Oncology 2022 17:18
  4. Although glioblastoma (GB) is associated with a devastating prognosis, a small proportion of patients achieve long-term survival rates. We herein present a matched-pair analysis of molecular factors found in l...

    Authors: Vivien N. Sommerlath, Daniel Buergy, Nima Etminan, Stefanie Brehmer, David Reuss, Gustavo R. Sarria, Marie-Christin Guiot, Daniel Hänggi, Frederik Wenz, Kevin Petrecca and Frank A. Giordano
    Citation: Radiation Oncology 2022 17:15
  5. The addition of consolidation chemotherapy to preoperative short-course radiotherapy during the prolonged interval between the completion of radiation and surgery in locally advanced rectal cancer (LARC) could...

    Authors: Haoyan Wu, Chuanwen Fan, Chao Fang, Libin Huang, Yuan Li and Zongguang Zhou
    Citation: Radiation Oncology 2022 17:14
  6. To define the clinical characteristics of irradiation-induced nasopharyngeal necrosis (INN) after intensity-modulated radiotherapy (IMRT) and identify the influence of treatment strategies on INN in primary na...

    Authors: Yi Xu, Yang Liu, Zekun Wang, Jingbo Wang, Jianghu Zhang, Xuesong Chen, Runye Wu, Qingfeng Liu, Yuan Qu, Kai Wang, Xiaodong Huang, Jingwei Luo, Li Gao, Guozhen Xu, Ye Zhang and Junlin Yi
    Citation: Radiation Oncology 2022 17:13
  7. To evaluate acute and late genitourinary and gastrointestinal toxicities and patient reported urinary and sexual function following accelerated, hypofractionated external beam radiotherapy to the prostate, sem...

    Authors: Christina Phuong, Jason W. Chan, Lisa Ni, Phillip Wall, Osama Mohamad, Anthony C. Wong, I.-Chow Hsu and Albert J. Chang
    Citation: Radiation Oncology 2022 17:12
  8. Although chemoradiotherapy (CRT) is one of the curative treatments for thoracic esophageal squamous cell carcinoma (ESCC) with submucosal invasion, the risk of local recurrence after CRT remains a clinical pro...

    Authors: Tomohiko Miyazaki, Miyako Myojin, Masao Hosokawa, Hidefumi Aoyama, Satoshi Okahara and Hiroaki Takahashi
    Citation: Radiation Oncology 2022 17:11
  9. Low dose radiotherapy (LDRT) of whole lungs with photon beams is a novel method for treating COVID-19 pneumonia. This study aimed to estimate cancer risks induced by lung LDRT for different radiotherapy delive...

    Authors: Amin Banaei, Bijan Hashemi and Mohsen Bakhshandeh
    Citation: Radiation Oncology 2022 17:10
  10. Chemoradiotherapy (CRT) followed by a brachytherapy (BT) boost is the standard of care for patients with locally advanced or recurrent gynecological cancer (LARGC). However, not every patient is suitable for B...

    Authors: Indrawati Hadi, Chukwuka Eze, Stephan Schönecker, Rieke von Bestenbostel, Paul Rogowski, Lukas Nierer, Raphael Bodensohn, Michael Reiner, Guillaume Landry, Claus Belka, Maximilian Niyazi and Stefanie Corradini
    Citation: Radiation Oncology 2022 17:8
  11. Concurrent chemoradiotherapy (CCRT) followed by durvalumab is the standard of care for unresectable locally-advanced non-small cell carcinoma (LA-NSCLC). However, a major concern about administration of durval...

    Authors: Hiroshi Mayahara, Kazuyuki Uehara, Aya Harada, Keiji Kitatani, Tomonori Yabuuchi, Shuichirou Miyazaki, Takeaki Ishihara, Hiroki Kawaguchi, Hikaru Kubota, Hideaki Okada, Taira Ninomaru, Chihiro Shindo and Akito Hata
    Citation: Radiation Oncology 2022 17:7
  12. To investigate the prognostic relevance of specific measurement parameters such as tumor diameter, tumor volume, tumor volume reduction rate (TVRR), and changes in the squamous cell carcinoma antigen (SCC-Ag) ...

    Authors: Wenjuan Chen, Siyi Xiu, Xingyun Xie, Huiming Guo, Yuanji Xu, Penggang Bai and Xiaoyi Xia
    Citation: Radiation Oncology 2022 17:6
  13. To characterise the motion of pulmonary tumours during stereotactic body radiation therapy (SBRT) and to evaluate different margins when creating the planning target volume (PTV) on a single 4D CT scan (4DCT).

    Authors: Pierre Trémolières, Ana Gonzalez-Moya, Amaury Paumier, Martine Mege, Julien Blanchecotte, Christelle Theotime, Damien Autret and Stéphane Dufreneix
    Citation: Radiation Oncology 2022 17:5
  14. Re-irradiation (re-RT) is a technically challenging task for which few standardized approaches exist. This is in part due to the lack of a common platform to assess dose tolerance in relation to toxicity in th...

    Authors: Eric D. Brooks, Xiaochun Wang, Brian De, Vivek Verma, Tyler D. Williamson, Rachel Hunter, Abdallah S. R. Mohamed, Matthew S. Ning, Xiaodong Zhang and Joe Y. Chang
    Citation: Radiation Oncology 2022 17:4
  15. High-quality radiotherapy (RT) planning for children and young adults with primary brain tumours is essential to minimize the risk of late treatment effects. The feasibility of using automated machine-learning...

    Authors: Derek S. Tsang, Grace Tsui, Chris McIntosh, Thomas Purdie, Glenn Bauman, Hitesh Dama, Normand Laperriere, Barbara-Ann Millar, David B. Shultz, Sameera Ahmed, Mohammad Khandwala and David C. Hodgson
    Citation: Radiation Oncology 2022 17:3
  16. Adjuvant radiotherapy following surgery reduces the local recurrence and improves the prognosis. However, a considerable part of patients developed digestive reaction in daily treatment. In order to explore th...

    Authors: Dong Yang, Ying Piao, Fengshun Yuan, Hongtao Chen, Ding Zhang and Xianming Li
    Citation: Radiation Oncology 2022 17:2
  17. Cardiac effects after breast cancer radiation therapy potentially affect more patients as survival improves. The heart’s heterogeneous radiation exposure and composition of functional structures call for estab...

    Authors: Marcus Stockinger, Heiko Karle, Hannes Rennau, Sabine Sebb, Ulrich Wolf, Julia Remmele, Sandra Bührdel, Detlef Bartkowiak, Maria Blettner, Heinz Schmidberger and Daniel Wollschläger
    Citation: Radiation Oncology 2021 16:241
  18. Radiation therapy is an integral part of the multimodal primary therapy of glioblastomas. As the overall prognosis in this tumor entity remains unfavorable, current research is focused on additional drug thera...

    Authors: Laila König, Cornelia Jäkel, Nikolaus von Knebel Doeberitz, Meinhard Kieser, Fabian Eberle, Marc Münter, Jürgen Debus and Klaus Herfarth
    Citation: Radiation Oncology 2021 16:240
  19. Radio-chemotherapy with CDDP is the standard for H&N squamous cell cancer. CDDP 100 mg/m2/q3 is the standard; alternative schedules are used to reduce toxicity, mostly 40 mg/m2/q1.

    Authors: Michela Buglione, Daniela Alterio, Marta Maddalo, Diana Greco, Marianna Alessandra Gerardi, Davide Tomasini, Ludovica Pegurri, Matteo Augugliaro, Giulia Marvaso, Irene Turturici, Andrea Guerini, Mohssen Ansarin, Luigi Spiazzi, Loredana Costa, Maria Cossu Rocca, Stefano Maria Magrini…
    Citation: Radiation Oncology 2021 16:239
  20. This study presents an analysis (efficacy and toxicity) of outcomes in patients with skull-base chordomas or chondrosarcomas treated with a fixed horizontal pencil proton beam.

    Authors: Konstantin Gordon, Igor Gulidov, Sergey Koryakin, Daniil Smyk, Tatyana Makeenkova, Danil Gogolin, Olga Lepilina, Olga Golovanova, Alexey Semenov, Sergey Dujenko, Kira Medvedeva and Yuri Mardynsky
    Citation: Radiation Oncology 2021 16:238
  21. The study aimed to compare the efficacy of osimertinib plus cranial radiotherapy (RT) with osimertinib alone in advanced non-small-cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (...

    Authors: Xiaoyang Zhai, Wanhu Li, Ji Li, Wenxiao Jia, Wang Jing, Yaru Tian, Shuhui Xu, Yuying Li, Hui Zhu and Jinming Yu
    Citation: Radiation Oncology 2021 16:233
  22. Immunotherapy has been administered to many patients with non-small-cell lung cancer (NSCLC). However, only few studies have examined toxicity in patients receiving an immune checkpoint inhibitor (ICI) after c...

    Authors: Jeong Yun Jang, Su Ssan Kim, Si Yeol Song, Yeon Joo Kim, Sung-woo Kim and Eun Kyung Choi
    Citation: Radiation Oncology 2021 16:231
  23. To identify the subset of patients with de novo nasopharyngeal carcinoma (NPC) for whom [18F] fluorodeoxyglucose positron emission tomography and computed tomography (18F-FDG PET/CT) should be recommended, and to...

    Authors: Chuanben Chen, Ting Xu, Xiufang Qiu, Shihan Xie, Ziqing You, Yixin Hu, Yinghong Zheng, Zewei Liang, Chaoxiong Huang, Taojun Chen, Li Li, Jing Liu and Zhaodong Fei
    Citation: Radiation Oncology 2021 16:229
  24. Neuroblastoma is a common extracranial malignant tumor in children. Its main treatment modality is a combination of chemotherapy, radiotherapy, and surgery. Given the advances in chemotherapy regimens and the ...

    Authors: Hongnan Zhen, Hui Guan, Jiabin Ma, Wenhui Wang, Shen Jing, Zheng Miao, Fuquan Zhang and Zhikai Liu
    Citation: Radiation Oncology 2021 16:228
  25. As cancer is developing into a chronic disease due to longer survival, continuity and coordination of oncological care are becoming more important for patients. As radiation oncology departments are an integra...

    Authors: Sebastian M. Christ, Maiwand Ahmadsei, Annina Seiler, Eugenia Vlaskou Badra, Jonas Willmann, Caroline Hertler and Matthias Guckenberger
    Citation: Radiation Oncology 2021 16:227
  26. Over the past decades, remarkable advancements in systemic drug therapy have improved the prognosis of patients with bone metastases. Individualization is required in external beam radiotherapy (EBRT) for bone...

    Authors: Kenji Makita, Yasushi Hamamoto, Hiromitsu Kanzaki, Masaaki Kataoka, Shuhei Yamamoto, Kei Nagasaki, Hirofumi Ishikawa, Noriko Takata, Shintaro Tsuruoka, Kotaro Uwatsu and Teruhito Kido
    Citation: Radiation Oncology 2021 16:225
  27. We aim to assess the risks associated with total body irradiation (TBI) delivered using a commercial dedicated Co-60 irradiator, and to evaluate inter-institutional and inter-professional variations in the est...

    Authors: Shahbaz Ahmed, Todd Bossenberger, Adrian Nalichowski, Jeremy S. Bredfeldt, Sarah Bartlett, Kristen Bertone, Michael Dominello, Mark Dziemianowicz, Melanie Komajda, G. Mike Makrigiorgos, Karen J. Marcus, Andrea Ng, Marvin Thomas and Jay Burmeister
    Citation: Radiation Oncology 2021 16:224
  28. The purpose of this study was to compare the treatment efficacy and safety of re-irradiation (re-RT) using stereotactic ablative radiotherapy (SABR) and initial SABR for primary, recurrent lung cancer or metas...

    Authors: Tae Hoon Lee, Dong-Yun Kim, Hong-Gyun Wu, Joo Ho Lee and Hak Jae Kim
    Citation: Radiation Oncology 2021 16:222
  29. The purpose of this study was to develop a model using dose volume histogram (DVH) and dosiomic features to predict the risk of radiation pneumonitis (RP) in the treatment of esophageal cancer with radiation t...

    Authors: Chanon Puttanawarut, Nat Sirirutbunkajorn, Suphalak Khachonkham, Poompis Pattaranutaporn and Yodchanan Wongsawat
    Citation: Radiation Oncology 2021 16:220
  30. Neoadjuvant chemoradiotherapy (nCRT) followed by surgery is a standard treatment modality for locally-advanced esophageal cancer. However, patients who achieve clinical complete response (cCR) after nCRT have ...

    Authors: Jaehyeon Park, Ji Woon Yea, Se An Oh and Jae Won Park
    Citation: Radiation Oncology 2021 16:219
  31. To determine the optimal volume of barium for oesophageal localisation on cone-beam CT (CBCT) for locally-advanced non-small cell lung cancers (NSCLC) and quantify the interfraction oesophageal movement relati...

    Authors: Katrina Woodford, Vanessa Panettieri, Jeremy D. Ruben, Sidney Davis, Trieumy Tran Le, Stephanie Miller and Sashendra Senthi
    Citation: Radiation Oncology 2021 16:218
  32. Main purpose was to describe procedures and identify challenges in the implementation process of adaptive and non-adaptive MR-guided radiotherapy (MRgRT), especially new risks in workflow due to the new techni...

    Authors: Helena Isabel Garcia Schüler, Matea Pavic, Michael Mayinger, Nienke Weitkamp, Madalyne Chamberlain, Cäcilia Reiner, Claudia Linsenmeier, Panagiotis Balermpas, Jerome Krayenbühl, Matthias Guckenberger, Michael Baumgartl, Lotte Wilke, Stephanie Tanadini-Lang and Nicolaus Andratschke
    Citation: Radiation Oncology 2021 16:217
  33. To evaluate the efficacy of concurrent chemoradiotherapy (CCRT) in subgroups of stage III nasopharyngeal carcinoma (NPC) in the context of intensity-modulated radiotherapy (IMRT).

    Authors: Lei Wang, Zheng Wu, Wanqin Cheng, Dehuan Xie, Feifei Lin, Liangping Xia and Yong Su
    Citation: Radiation Oncology 2021 16:215
  34. Androgen deprivation therapy (ADT) used for prostate cancer (PCa) management is associated with metabolic and anthropometric toxicity. Metformin given concurrent to ADT is hypothesized to counteract these chan...

    Authors: Julian O. Kim, Megan O. McDonald, Aldrich Ong, Rashmi Koul, Arbind Dubey, William Hunter, Shahida Ahmed, Harvey Quon, Don Yee, Matthew Parliament, Gokulan Sivananthan, Brita Danielson, Lindsay Rowe, Sunita Ghosh and Nawaid Usmani
    Citation: Radiation Oncology 2021 16:212
  35. Radiotherapy may work synergistically with immunotherapy and targeted agents. We aimed to assess the safety and outcomes of stereotactic body radiotherapy (SBRT) plus non-first-line programmed death-1 (PD-1) i...

    Authors: Yang Liu, Zhiling Zhang, Ruiqi Liu, Wensu Wei, Zitong Zhang, Lixin Mai, Shengjie Guo, Hui Han, Fangjian Zhou, Liru He and Pei Dong
    Citation: Radiation Oncology 2021 16:211
  36. Radiotherapy (RT) might lead to atherosclerotic plaque buildup and coronary artery stenosis of breast cancer (BC) survivors, and coronary artery calcium (CAC) might be a sign of preclinical atherosclerosis. Th...

    Authors: Yu-Hsuan Lai, Helen H. W. Chen and Yi-Shan Tsai
    Citation: Radiation Oncology 2021 16:210
  37. Through recent advances in cancer care, the number of long-term survivors has continuously increased. As a result, repetitive use of local radiotherapy for curative or palliative indications might have increas...

    Authors: Sebastian M. Christ, Maiwand Ahmadsei, Lotte Wilke, Anja Kühnis, Matea Pavic, Stephanie Tanadini-Lang and Matthias Guckenberger
    Citation: Radiation Oncology 2021 16:208
  38. There is still no definitely therapeutic evidence of a beneficial effect of chemotherapy with radiotherapy for older patients with esophageal squamous cell carcinoma (ESCC). We aim to determine the influence o...

    Authors: Haishan Wu, Yilin Yu, Qunhao Zheng, Tianxiu Liu, Yahua Wu, Zhiping Wang, Hongying Zheng, Lingyun Liu and Jiancheng Li
    Citation: Radiation Oncology 2021 16:207
  39. The COVID-19 pandemic has stripped many medical students worldwide of their right to quality education. In response, we developed hybrid courses involving aspects of both online and in-person teaching for radi...

    Authors: Tae Hyung Kim, Jin Sung Kim, Hong In Yoon, Joongyo Lee, Jason Joon Bock Lee, Hwa Kyung Byun, Yeona Cho, Yong Bae Kim, Ik Jae Lee, Kyung Hwan Kim and Jee Suk Chang
    Citation: Radiation Oncology 2021 16:204
  40. To study the performance of a proposed deep learning-based autocontouring system in delineating organs at risk (OARs) in breast radiotherapy with a group of experts.

    Authors: Hwa Kyung Byun, Jee Suk Chang, Min Seo Choi, Jaehee Chun, Jinhong Jung, Chiyoung Jeong, Jin Sung Kim, Yongjin Chang, Seung Yeun Chung, Seungryul Lee and Yong Bae Kim
    Citation: Radiation Oncology 2021 16:203
  41. To develop a nomogram model for predicting local progress-free survival (LPFS) in esophageal squamous cell carcinoma (ESCC) patients treated with concurrent chemo-radiotherapy (CCRT).

    Authors: He-San Luo, Ying-Ying Chen, Wei-Zhen Huang, Sheng-Xi Wu, Shao-Fu Huang, Hong-Yao Xu, Ren-Liang Xue, Ze-Sen Du, Xu-Yuan Li, Lian-Xin Lin and He-Cheng Huang
    Citation: Radiation Oncology 2021 16:201
  42. Second head and neck neuroendocrine carcinoma (NEC) after radical radiotherapy for nasopharyngeal carcinoma (NPC) treatment is rarely reported. The prognosis of second cancer is poor, and our research focuses ...

    Authors: Ying-peng Peng, Qiao-dan Liu, Yu-jing Lin, Shun-li Peng, Rong Wang, Xi-wei Xu, Wei Wei, Gui-hua Zhong, Yu-ling Zhou, Ya-qin Zhang, Ye Liu, Si-yang Wang, Hai-yu Hong and Zhi-gang Liu
    Citation: Radiation Oncology 2021 16:198
  43. Approximately one third of cancer patients will develop spinal metastases, that can be associated with back pain, neurological symptoms and deterioration in performance status. Stereotactic radiosurgery (SRS) ...

    Authors: Niccolò Giaj-Levra, Vanessa Figlia, Francesco Cuccia, Rosario Mazzola, Luca Nicosia, Francesco Ricchetti, Michele Rigo, Giorgio Attinà, Claudio Vitale, Gianluisa Sicignano, Antonio De Simone, Stefania Naccarato, Ruggero Ruggieri and Filippo Alongi
    Citation: Radiation Oncology 2021 16:197
  44. Adjuvant therapy is a promising treatment to improve the prognosis of cancer patients, however, the evidence base driving recommendations for adjuvant radiotherapy (ART) or chemotherapy (ACT) in retroperitonea...

    Authors: Xiangji Li, Tong Wu, Mengmeng Xiao, Shanshan Wu, Li Min and Chenghua Luo
    Citation: Radiation Oncology 2021 16:196
  45. Whether adjuvant chemotherapy (AC) after concurrent chemoradiotherapy (CCRT) could provide benefit to esophageal squamous cell carcinoma (ESCC) patients is controversial. Therefore, we decided to investigate t...

    Authors: Ao Liu, Yalin Wang, Xin Wang, Liqiong Zhu, Yu Nie and Minghuan Li
    Citation: Radiation Oncology 2021 16:195
  46. Systemic response to local anticancer treatment is a phenomenon called ‘abscopal effect’. The immune system is thought to play a pivotal role in its occurrence. To date, several cases have been reported, parti...

    Authors: Oliver Vilinovszki, Nicolaus Andratschke, Martin Huellner, Alessandra Curioni-Fontecedro and Stephanie G. C. Kroeze
    Citation: Radiation Oncology 2021 16:194
  47. To determine the most appropriate radiologic criteria of metastatic retropharyngeal lymph nodes (RLNs) in patients with maxillary sinus cancer (MSC).

    Authors: Yasuo Kosugi, Michimasa Suzuki, Mitsuhisa Fujimaki, Shinichi Ohba, Fumihiko Matsumoto, Yoichi Muramoto, Terufumi Kawamoto, Masaki Oshima, Naoto Shikama and Keisuke Sasai
    Citation: Radiation Oncology 2021 16:190

Annual Journal Metrics

  • 2022 Citation Impact
    3.6 - 2-year Impact Factor
    3.8 - 5-year Impact Factor
    1.370 - SNIP (Source Normalized Impact per Paper)
    1.037 - SJR (SCImago Journal Rank)

    2023 Speed
    16 days submission to first editorial decision for all manuscripts (Median)
    132 days submission to accept (Median)

    2023 Usage 
    605 Altmetric mentions